Ll. Von Moltke et al., Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors, J CLIN PHAR, 41(1), 2001, pp. 85-91
The capacity of three clinically available nonnucleoside reverse transcript
ase inhibitors (NNRTIs) to inhibit the activity of human cytochromes P450 (
CYPs) was studied in vitro using human liver microsomes. Delavirdine, nevir
apine, and efavirenz produced negligible inhibition of phenacetin O-deethyl
ation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6). Nevirapine did
not inhibit hydroxylation of tolbutamide (CYP2C9) or S-mephenytoin (CYP2C1
9), but these CYP isoforms were importantly inhibited by delavirdine and ef
avirenz. This indicates the likelihood of significantly impaired clearance
of CYP2C substrate drugs (such as phenytoin, tolbutamide, and warfarin) upo
n initial exposure to these two NNRTIs. Delavirdine and efavirenz (but not
nevirapine) also were strong inhibitors of CYP3A, consistent with clinical
hazards of initial cotreatment with either of these drugs and substrates of
CYP3A. The in vitro microsomal model provides relevant predictive data on
probable drug interactions with NNRTIs when the mechanism is inhibition of
CYP-mediated drug biotransformation. However, the model does not in corpora
te interactions attributable to enzyme induction. Journal of Clinical Pharm
acology, 2001;41:85-91 (C) 2001 the American College of Clinical Pharmacolo
gy.